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Abstract
Background: Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while
circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there
is not a universally accepted standardized protocol to identify and quantify these cells and its clinical relevancy remains to
be established.
Objectives: To quantify CEC and CEP in patients with venous thromboembolism (VTE) and with myeloproliferative
neoplasms (MPN), to characterize the CEC for the expression of activation (CD54, CD62E) and procoagulant (CD142) markers
and to investigate whether they correlate with other clinical and laboratory data.
Patients and Methods: Sixteen patients with VTE, 17 patients with MPN and 20 healthy individuals were studied. The CEC
and CEP were quantified and characterized in the blood using flow cytometry, and the demographic, clinical and laboratory
data were obtained from hospital records.
Results: We found the CEC counts were higher in both patient groups as compared to controls, whereas increased numbers
of CEP were found only in patients with MPN. In addition, all disease groups had higher numbers of CD62E+ CEC as
compared to controls, whereas only patients with VTE had increased numbers of CD142+ and CD54+ CEC. Moreover, the
numbers of total and CD62+ CEC correlated positively with the white blood cells (WBC) counts in both groups of patients,
while the numbers of CEP correlated positively with the WBC counts only in patients with MPN. In addition, in patients with
VTE a positive correlation was found between the numbers of CD54+ CEC and the antithrombin levels, as well as between
the CD142+ CEC counts and the number of thrombotic events.
Conclusions: Our study suggests that CEC counts may reveal endothelial injury in patients with VTE and MPN and that CEC
may express different activation-related phenotypes depending on the disease status.
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Introduction
The vascular endothelium is strategically located at the interface
between tissues and blood [1], being composed by endothelial cells
(EC) that form the inner lining of blood vessels [2]. Endothelial
cells are metabolically active and play a critical role in many
physiological processes, including the maintenance of vascular
integrity and the generation of an anti-thrombotic surface [3].
When endothelial injury occurs, the vascular surface acts as a
prothrombotic environment, the induction of tissue factor (TF,
CD142) and other procoagulant molecules on the EC surface
being one of the pivotal steps in this process [4]. Endothelial lesion
is also accompanied by the expression of adhesion molecules on
the EC membrane, including P-Selectin (CD62P), E-Selectin
(CD62E), intercellular adhesion molecule type 1 (ICAM-1, CD54)
and vascular cell adhesion molecule type 1 (VCAM-1) [1,5,6].
These molecules cause leukocyte recruitment and attachment to
the EC, suggesting a role in vascular occlusion [6].
Over the last years it has been proposed that circulating
endothelial cells (CEC) may reflect endothelial injury, increased
numbers of CEC being observed in different pathological
conditions [7,8,9,10]. In addition, a bone-marrow derived cell
population - the circulating endothelial progenitor cells (CEP) - has
been highlighted, and it has been suggested that these cells
contribute to vascular repair [11,12]. Nevertheless, the number of
CEC and CEP in the peripheral blood are exquisitely low, those
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cells representing about 0.01% to 0.0001% of the mononuclear
cells [13], and their quantification is not yet standardized. Of the
different methods used, flow cytometry seems the most promising,
allowing a rapid multiparametric analysis of these cells [11].
Venous thromboembolism (VTE) is a chronic vascular disease
with an average incidence of 117 cases per 100.000 individuals/
year [14], which manifests by thrombus formation in the venous
system and usually occurs in the legs or as pulmonary embolism
[15,16]. The known risk factors for VTE, that can be genetic and/
or acquired, influence the stasis and the hypercoagulability [15].
The genetic risk factors known to be associated with inherited
thrombophilia include the gain (e.g. factor V Leiden and
prothrombin 20210A mutations) or the loss (i.e., deficiencies in
the coagulation inhibitors, antithrombin, protein C and protein S)
of coagulation function [17]. Acquired risk factors, such as age,
surgery, trauma, immobilization, cancer, pregnancy and the
puerperium are useful for estimating the risk of VTE [18].
Nevertheless, they provide little insight into the mechanisms
initiating VTE [19], which still needs to be clarified, namely
concerning the interaction between the EC and constituents of the
blood. [20]
Essential thrombocythaemia (ET) and polycythaemia vera (PV)
are myeloproliferative neoplasms (MPN) whose clinical course is
mainly characterized by an increased incidence of vascular
complications and a tendency to progress into myelofibrosis or
acute myeloid leukaemia [21,22]. Several factors are involved in
the pathogenesis of thrombosis occurring in MPN, including
patient-related, such as the age, previous thrombotic events (TE),
and disease-related (i.e. the presence of JAK2V617F mutation and
the baseline leukocyte count) factors, some of which have been
used to stratify patients into low and high risk categories and to
define treatment strategies [23,24,25].
Based on the assumption that CEC and CEP are potential
biomarkers for monitoring the vascular integrity and regenerative
ability, respectively, we hypothesized that these EC populations
have a different expression in the blood of patients with increased
risk of thrombosis as compared to healthy individuals. Therefore,
we decided to quantify and characterize these cells by flow
cytometry in the blood of patients with VTE and patients with
MPN, either ET or PV. We also searched for possible correlations
between CEC and CEP counts, as well as the CEC expression of
activation-induced adhesion molecules and procoagulant markers,
with the number of TE, laboratory data and other thrombosis risk
factors.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Committee of the
Centro Hospitalar do Porto and all participants gave written
informed consent.
Study design
A total of 33 adult patients (16 patients with VTE and 17
patients with MPN) recruited from the Clinical Haematology
consultation from the Hospital de Santo Anto´nio, Centro
Hospitalar do Porto (Porto, Portugal) were studied. The CEC
and CEP were quantified and characterized in the peripheral
blood using flow cytometry, and the demographic, clinical and
laboratory data were obtained from the hospital records. The
results were compared with those obtained in 20 healthy
individuals (benevolent blood donors), recruited from the hospital
blood bank.
Subjects
The VTE group consisted of 16 patients, 12 females and 4
males, with a median age of 38 years (range: 22–65 years) who
have had at least one venous TE and that have been selected for
thrombophilia testing. Venous thromboembolism was defined as
deep vein thrombosis, pulmonary embolism or objectively
documented thrombosis of deep veins elsewhere in the body
[15], which could be unprovoked, i.e. TE occurred without a
known risk factors, or manifesting after exposure to triggering
circumstances such as surgery, trauma and pregnancy [26].
Criteria for thrombophilia testing were the first thrombosis
occurring before age of 50 years, family history of thromboem-
bolism and thrombosis in unusual sites (e.g. cerebral, visceral and
upper extremity veins) [27]. The MPN group included 9 patients
with ET (7 females and 2 males) and 8 patients with PV (1 female
and 7 males), who fulfilled the criteria for the diagnosis, as defined
by the World Health Organization in 2008 [21,22]. The median
age of the patients with MPN was 64 years, ranging from 32 to 83
years (ET: 57 years, ranging from 32 to 83 years; PV: 64.5 years,
ranging from 59 to 82 years). Patients with VTE and MPN having
less than a month over the last TE, or having an acute coronary
disease were excluded. Other exclusion criteria were the presence
of acute inflammatory processes, active cancers, autoimmune
diseases, diabetes mellitus, hepatic and renal dysfunction; patients
that had been hospitalized or have had puerperium during the
month before the study were also excluded.
Twenty benevolent blood donors, 10 females and 10 males, with
a median age of 49.5 years (range: 34–64 years) were used as
controls. Blood donors at the first blood donation or that have had
recent diseases (,3 months) were excluded.
Clinical and laboratory data
Besides demographic data, we also recorded the number and
location of the TE, as well as the blood counts in all participants.
For patients with VTE, the existence of familiar history of TE,
personal obstetric events associated with increased risk for
thrombosis and other parameters tested in the routine workflow
for the screening of thrombophilia, such as the fibrinogen,
homocysteine, D-dimers, factor VIII, protein S, protein C and
antithrombin (AT) plasma levels, factor V Leiden, prothrombin
G20210A and anti-phospholipid antibodies were also registered.
Patients with MPN were investigated for the presence of the JAK2
mutation.
Blood sample collection
Peripheral blood samples used for flow cytometry were collected
into a 3 ml tube containing tri-potassium ethylene-diamine-tetra-
acetic acid (K3-EDTA). In order to avoid the artificial increase in
CEC due to venipuncture, the first two millilitres of blood were
discarded.
Flow cytometry studies
Technical procedure. Cell staining was performed using a
single platform lyse-no-wash direct immunofluorescence tech-
nique. Briefly, two hundred microliters of whole blood were
incubated for 15 minutes, at room temperature, with two different
combinations of monoclonal antibodies (mAb) conjugated with
different fluorochromes (Table 1). In order to quantify CEC and
CEP, the first staining (anti-CD62E FITC/anti-CD146 PE/anti-
CD45 PerCP/anti-CD133 APC) was performed in fluorescent
beads containing tubes prepared for absolute cell counting (BD
TrucountTM tubes; Becton Dickinson, San Jose, CA) (BD),
whereas the second staining (anti-CD142 FITC/anti-CD146
Circulating Endothelial Cells in Thrombosis
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PE/anti-CD45 PerCP/anti-CD54 APC) was done using normal
12675 mm polypropylene tubes (BD). After incubation, red cell
lysis and cell fixation were performed by adding 1 ml of pre-
diluted BD FACS Lysing Solution for another 15 minutes, just
following by the addition of 2 ml of phosphate buffered saline
(PBS) to minimize the effects of the lysing solution on cell integrity.
In order to reduce the background, both solutions were previously
filtrated with 0.2 ml filters (Thermo Scientific NALGENE). The
flow cytometry acquisition was carried on a FACSCalibur (BD)
equipped with blue argon and red diode lasers, after a long
cleaning procedure (.50 minutes). The instrument performance
was monitored daily using the BD CaliBRITETM beads. The BD
Cell Quest ProTM software was used for data acquisition. The BD
Paint-A-Gate ProTM (BD) and the InfinicytTM (Cytognos,
Salamanca, Spain) programs were used for data analysis.
Data acquisition and analysis. The detection, quantifica-
tion and characterization of CEC and CEP were made using a
gating strategy during sample acquisition (Fig. 1), and analysis
(Fig. 2). During sample acquisition, a threshold was established on
the forward scatter (FSC) in order to exclude debris, except for the
BD TrucountTM blood sample tube, in order to include the beads.
The CEC and the CEP were identified based on their typical
immunophenotype: CD45-CD146+CD133- and
CD45+lowCD146+CD133+, respectively. Activated CEC were
identified based on the expression of adhesion or procoagulant
molecules (CD54, CD62E and CD142). The absolute numbers of
total CEC and CEP were calculated according with the BD
TrucountTM tube manufacturer’s recommendations. The absolute
numbers of activated CEC were calculated by multiplying the
absolute numbers of the total CEC by the percentage of activated
CEC, for each marker in the study. As CEC are very rare events,
all samples were acquired till the end.
Statistics
Statistical analysis was performed using the SPSS statistical
software (version 13.0). For each continuous quantitative variable,
the median, minimum and maximum values were calculated. The
Mann-Whitney test was used to compare absolute numbers of total
CEC and CEP, as well as the absolute numbers of activated CEC
between groups, whereas the Spearman’s test was used to correlate
variables. P values less than 0.05 were considered statistically
significant.
Results
Clinical data and risk factors for thrombosis
The demographic and clinical data of patients and controls are
presented in Table 2. The distribution of gender in patients with
MPN and VTE did not differ significantly to that observed in
controls. The VTE group was found to be similar to the control
group concerning the distribution of age, but patients MPN were
significantly older than controls (p = 0.001). Although there is not
age match between patients with MPN and controls, we verified
that the age is not associated with the variables of interest in our
study, not having a confounding effect (Tables S1 and S2 in File
S1).
In the VTE group the median number of TE was 1 (range: 1–4),
while in the MPN group the median was 0 (range: 0–1) (Table 2).
Of the 17 patients with MPN, 5 had thrombosis, belonging 2 to
the ET subgroup and 3 to the PV subgroup. We did not find any
correlation between gender and age with the number and the type
of TE (data not shown). At the time of the study, 2 patients with
VTE and 16 patients with MPN (8 ET patients and 8 PV patients)
were receiving therapy.
Patients with VTE had significantly lower haematocrit values
than controls (Table 3), as previously described [28]. On the other
hand, patients with MPN had a significantly higher number of
platelets and white blood cells (WBC) when compared to controls;
similar results were obtained when the ET and PV subgroups were
analyzed separately. Moreover, patients with PV had significantly
higher haemoglobin and haematocrit values than controls. We did
not find any correlation between the WBC, platelets, haematocrit
and haemoglobin values and the number of TE in MPN group,
neither in the ET and PV subgroups (data not shown). No VTE
patients had the Factor V Leiden mutation but one patient was
heterozygous for the prothrombin gene G20210 G-.A mutation.
The Jak2 mutation was detected in 11 patients of the patients with
MPN (61.1%), 5 patients with ET (55.6%) and 6 patients with PV
(75.0%). We did not observe any correlation between the blood
counts and the presence of Jak2 mutation, neither in the MPN
group as an all, nor in the ET and in the PV subgroups. In the
VTE group there were several patients with high levels of
fibrinogen, factor VIII, D-dimers and homocysteine and/or with
low levels of free protein S and protein C (Table 4). Nevertheless
there was no correlation between these parameters and the
number of thrombosis in VTE patients.
Table 1. Characteristics of the monoclonal antibodies used in this study.
Cluster designation Clone Fluorochromes Supplier Specificity
Expression on endothelial
cells
CD45 2D1 PerCP BD Bioscience Leukocyte Common Antigen (LCA) Progenitor*
CD54 HA58 APC BD Pharmingen Intercellular Adhesion Molecule 1
(ICAM-1)
Activated
CD62E BBIG-E5 (10C10) FITC R&D Systems E-Selectin Activated
CD133 AC133 APC Miltenyi Biotec Prominin 1 (PROM1) Progenitor
CD142 VD8 FITC American Diagnostica Tissue factor Activated
CD146 P1H12 PE BD Pharmingen Melanoma cell adhesion molecule
(MCAM or Mel-CAM)
All
Abbreviations: PerCP, peridin-chlorophyll protein; APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
*CD45 has been described as being absent on mature endothelial cells and expressed at very low levels on endothelial progenitor cells.
doi:10.1371/journal.pone.0081574.t001
Circulating Endothelial Cells in Thrombosis
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Circulating endothelial cells
The median count of CEC in healthy individuals was 504 cells/
ml, ranging from 186 to 1371 (Table 5). Both patient groups had a
statistically significant increase in the CEC numbers, as compared
to controls. The highest CEC numbers were observed in MPN
patients (median of 1305 cells/ml; range: 499–4616), while VTE
patients had intermediate numbers of CEC (median of 1231 cells/
ml, range: 446–4272). In addition, patients with ET had higher
numbers of CEC (1305 cells/ml, range: 499–4239) than PV
patients (1231 cells/ml, range: 594–4616).
Circulating endothelial progenitor cells
The median count of CEP in healthy individuals was 295 cells/
ml, ranging from 0 to 2110 (Table 5). The number of CEP in
patients with MPN (311 cells/ml, ranging from 0 to 3791) was
higher than that observed in controls, although differences were
not statistically significant. Similar results were obtained when the
ET and PV subgroups were analysed separately. In contrast,
patients with VTE had a lower CEP count than controls
(168 cells/ml; range 0–1698) (p,0.05).
Figure 1. Data acquisition strategy used to identify and quantify the circulating endothelial cells. Our acquisition gating strategy assures
the quantification of the circulating endothelial cells (CEC) and endothelial progenitor cells (CEP) without creating enormous FCS2.0 data files. Dot
plot A illustrates the initial gating based on the FSC/SSC parameters (R1), in order to exclude events with lower FSC/SSC, which comprise mainly
debris and platelets; dot plot B shows the events within the gate (R1), and includes a gate for TrucountTM beads (R2) and another gate for
mononuclear cells (R3); dot plot C shows the events within the gate R2 and includes a new gate only for the beads (R4); dot plot D shows the events
within the gate of mononuclear cells (R3) and contains a new gate only for CD146+ cells, either CD45- or CD45+ (R5). All the events that were inside
the R4 (beads) or R5 (CD146+ cells) regions were acquired and stored.
doi:10.1371/journal.pone.0081574.g001
Circulating Endothelial Cells in Thrombosis
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Activated circulating endothelial cells
Activated CEC were identified based on the expression of
adhesion (CD54, CD62E) or procoagulant (CD142) molecules
(Table 6).
All patient groups had higher numbers of CD62E+ CEC, as
compared to controls (145 cells/ml, ranging from 0 to 604)
(p,0.001). The median count of CD62E+ CEC in VTE patients
was 683 cells/ml, ranging from 205 to 2990, similar values were
observed in patients with MPN (677 cells/ml, ranging from 200 to
2390).
We also notice that all groups had higher numbers of CD54+
CEC as compared to healthy individuals, who had a median
number of CD54+ CEC of 72 cells/ml, ranging from 0 to 227.
However differences reached statistical significance only for VTE
patients (p,0.001), who showed a median number of CD54+
CEC of 238 cells/ml, ranging from 29 to 1179.
In that concerning the expression of the CD142 procoagulant
marker (TF), we found that only VTE patients had significantly
higher numbers of CD142+ CEC (median: 309 cells/ml; range
93–2532) than healthy control (median: 77 cells/ml; range: 0–366)
(p,0.001), no differences being observed between the CD142+
CEC counts from patients with MPN (ET or PV) and controls.
Correlation between total circulating endothelial cells,
activated endothelial cells and endothelial cell precursors
with other clinical and laboratory data
In VTE and MPN groups we found a positive correlation
between the total number of CEC and the WBC count (VTE:
r = 0.515, p = 0.041; MPN: r = 0.738, p = 0.001) and between the
number of CD62E+ CEC and the WBC count (VTE: r = 0.605,
p = 0.013; MPN: r = 0.610, p= 0.009). Moreover, patients with
MPN also had a positive correlation between the number of CEP
and the WBC count (r = 0.846, p,0.001) and a negative
correlation between the CD54+ CEC and the platelet count
(r =20.508, p = 0.037). We did not find any correlation between
the number of total and activated CEC and CEP and the presence
of Jak2 mutation in MPN patients (data not shown).
In patients with VTE, we observed that the number of CD142+
CEC correlated with the number of thrombosis (r = 0.568,
Figure 2. Data analysis strategy used to identify and quantify the circulating endothelial cells. Our data analysis gating strategy assures
the identification and quantification of the circulating endothelial cells (CEC) and endothelial progenitor cells (CEP), among stored CD146+ cells.
Using the Paint-a-GateTM or the InfinicytTM software we first identified the beads (blue dots) in the CD45 vs. CD146 dot plot (A); after that, we selected
the total CD146+ events (green dots) (B, for selection of CD146+ cells; C, showing the light scatter properties of the cells); after excluding the CD146-
cells (D to F), we finally were obtained the CEC (CD45-CD146+, yellow dots), the CEP (CD45+lowCD146+, red dots), activated lymphocytes
(CD45+highCD146+, green dots), as well as the beads (blue dots), being then able to perform CEC and CEP quantification.
doi:10.1371/journal.pone.0081574.g002
Circulating Endothelial Cells in Thrombosis
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p= 0.022). When investigating the correlation between total CEC,
total CEP and activated CEC counts and other thrombophilia
factors, we found that the number of CD54+ CEC correlated
positively with plasma level of AT (r = 0.558, p = 0.025).
Discussion
The identification and quantification of the EC in the blood is
technically very difficult and not yet well standardized [13], which
probably explains the wide range of CEC numbers described in
healthy individuals (4 to 7900 cells/ml) [10,29]. Nevertheless,
efforts have been made to define correctly the CEC, as well as the
CEP, and there is evidence that these two EC populations can
reveal endothelial injury and endothelial repair, respectively. CEC
are thought to be released from the vessel wall after vascular
damage, while CEP are derived from the bone marrow and
mobilized to injury sites in order to assist in the vascular repair
[7,8,11,30,31] In healthy individuals there is a balance between
CEC and CEP that preserves cell integrity and homeostasis [32],
this balance being disrupted in some pathological conditions, in
which there are increased numbers of CEC and/or decreased
numbers of CEP [7,8,9,10,31,33,34,35,36]. Moreover, it has been
found that increased numbers of CEC were accompanied by
alterations of endothelial soluble markers [37]. Thus, it seems
reasonable to assume that the simultaneous study of CEC and
CEP can reveal endothelial state and actual function [11,32,38].
In this study we challenged a new approach to analyzing the
CEC and CEP, using a four-color staining lyse-no-wash flow
cytometry procedure together with specific acquisition and
analysis strategies. Using this procedure, we identified the CEC
and the CEP based on the differential expression of the CD45,
CD146 and CD133 molecules. In accordance, CD146 is widely
used to recognize CEC, and also identifies CEP [39]. Although T-
cells may also express CD146, using CD45, a pan leukocyte
marker, it is possible to discriminate CD45+highCD146+ T-cells
from CEC, which are CD45-CD146+, and from CEP, which are
CD45+lowCD146+ [13]. In addition, CD133, a progenitor
molecule expressed on the CEP and haematopoietic stem cells,
Table 2. Demographic and clinical data of patients with VTE, patients with MPN and controls.
Demographic and clinical features Controls VTE MPN MPN (ET) MPN (PV)
Number of cases 20 16 17 9 8
Gender (males: females) 10:10 4:12 9:8 2:7 7:1
Age (years) 49.5 (34–64) 38 (22–65) 64 (32–83) 57 (32–83) 64.5 (59–82)
Number of patients with TE, n (%) 0 16 (100.0) 5 (29.4) 2 (22.2) 3 (37.5)
Number of TE per patient 0 (0) 1 (1–4) 0 (0–1) 0 (0–1) 0 (0–1)
Type of TE, n (%) Femoral and iliofemoral 0 (0) 14 (87.5) 1 (5.9) 0 (0) 1 (12.5)
Pulmonary thromboembolism 0 (0) 1 (6.3) 0 (0) 0 (0) 0 (0)
Venous TE at unusual sites 0 (0) 2 (12.5) 3 (17.6) 2 (22.2) 1 (12.5)
Arterial thrombosis 0 (0) 1 (6.3) 1 (5.9) 0 (0) 1 (12.5)
Other clinical features, n (%) Family history of thrombosis 0 (0) 2 (12.5) NA NA NA
Recurrent miscarriages 0 (0) 0 (0) NA NA NA
Treatment, n (%) No treatment 20 (100.0) 14 (87.5) 1 (5.9) 1 (11.1) 0 (0)
Hydroxyurea 0 (0) 0 (0) 12 (70.6) 5 (55.6) 7 (87.5)
Antiplatelet drugs 0 (0) 0 (0) 7 (41.2) 6 (66.7) 1 (12.5)
Phlebotomies 0 (0) 0 (0) 5 (29.4) 0 (0) 5 (62.5)
Oral anticoagulants 0 (0) 1 (6.3) 2 (11.8) 0 (0) 2 (25.0)
Low molecular weight heparins 0 (0) 1 (6.3) 0 (0) 0 (0) 0 (0)
Abbreviations: ET, essential thrombocythaemia, VTE, venous thromboembolism; MPN, myeloproliferative neoplasms; PV, polycythaemia vera; TE, thromboembolic
events; NA, data not available.
Results are presented as median (minimum – maximum) values and as absolute (n) or relative (%) frequencies.
doi:10.1371/journal.pone.0081574.t002
Table 3. Blood cell counts in patients with VTE, patients with MPN and controls.
Blood counts Controls VTE P* MPN P* MPN (ET) P* MPN (PV) P*
HGB (g/dl) 14.1 (11.8–15.8) 13.5 (11.7–16.2) NS 14.5 (11.1–16.6) NS 13.5 (11.1–15.6) NS 14.8 (13.8–16.6) 0.021
HT (%) 42.1 (36.2–47.2) 39.6 (35.2–48.3) 0.042 44.0 (34.7–49.8) NS 40.5 (34.7–47.1) NS 46.2 (43.4–49.8) ,0.001
PLT (x109/l) 215 (149–306) 216.5 (169–364) NS 635 (154–1033) ,0.001 705 (567–1033) ,0.001 406 (154–1026) 0.011
WBC (x109/l) 6.5 (3.9–11.2) 6.8 (4.2–10.1) NS 11.6 (7.1–24.7) ,0.001 11.6 (7.3–24.7) ,0.001 10.4 (7.1–23.6) ,0.001
Abbreviations: ET, essential thrombocythaemia; VTE, venous thromboembolism; MPN, myeloproliferative neoplasms; PV, polycythaemia vera; HGB, haemoglobin; HT,
haematocrit; PLT, platelets; WBC, white blood cells; NS, not statistically significant.
Results are presented as median (minimum – maximum) values.
*Patients versus controls; Mann-Whitney test; p,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0081574.t003
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is absent in CEC [39,40,41]. Therefore, co-staining for CD146,
CD133 and CD45, allows to distinguish between CEP
(CD45+lowCD146+CD133+), CEC (CD45-CD146+CD33-), and
other blood cell types [39].
During acquisition we gated both CD45-CD146+ and
CD45+CD146+ events, which include CD146+ T-cells, the
identification of CEC being made only in the analysis step; this
gave the advantage of using activated T-cells to define the cut-off
for the expression of CD146 [42].
To the best of our knowledge, this is the first report in which
CEC and CEP were simultaneously quantified and, at the same
time, the CEC were characterized for the expression of the
activation (CD62E, CD54) and procoagulant (CD142) molecules
in patients with VTE and MPN. In that concerning the MPN
group, it is important to mention that most results from patients
with ET and PV were presented together because these subgroups
were small when considered individually and we did not find
significant statistic differences between them in most parameters.
In the present study, the median CEC counts in the control
group was 504 cells/ml, which is in the same range of values found
by another group [43]. Our results also showed that CEC
numbers are significantly higher in patients with VTE and MPN,
as compared to healthy individuals. Increased numbers of CEC in
patients with ET and PV have already been reported in a previous
study [29].
Of note, we found significantly lower numbers of CEP in
patients with VTE in comparison to those observed in controls.
Since there is evidence that CEP promote new vessel formation
and tissue vascularisation during ischemia [44], this observation
may indicate impaired endothelial repair in patients with VTE.
On the other hand, MPN patients showed higher numbers of
CEP, as compared to controls, although the difference was not
statistically significant. This finding is consistent with a previous
report showing higher numbers of CEP in the PV patients [45]
and could explain the increased microvessel density described in
patients with MPN [46].
Concerning the expression of activation- and procoagulant-
related molecules, we found that all disease groups analysed in this
study had higher counts of CD62+ CEC, as compared to controls.
On the contrary, only VTE patients showed significantly higher
CD54+ and CD142+ CEC numbers, suggesting that adhesion
molecules are involved in the vascular occlusion in these patients.
When correlating total- and activated-CEC numbers with blood
counts, we found a positive correlation between the WBC and the
CEC, as well as between the WBC and the CD62E+ CEC counts,
in both disease groups. The stronger and more significant
correlation observed in the MPN group, may indirectly indicate
the endothelial involvement in thrombosis, since it was previously
reported that leukocytosis is associated with thrombosis in patients
with MPN [47,48]. In addition, a positive correlation between the
WBC count and soluble CD62E was found in another study [49].
Our results are in conformity with the presence of inflammation,
as the WBC count is an inflammatory marker [50], being
accompanied with increased numbers of total and activated CEC.
In patients with MPN we also found a positive correlation
between the CEP and the WBC counts. It is well known that MPN
are stem cell disorders, suggesting that is accompanied also by an
increase in EC [51]. According to a previous study, there is
evidence that EC from patients with MPN originate from the same
Table 4. Other risk factors in patients with VTE.
Values in patients with VTE Reference values
Number of patients with VTE with abnormal
values (%)
Fibrinogen (g/l) 3.0 (2.1–5.0) 2.2–3.8 7 (43.8)
Factor VIIIc (%) 155.3 (74.0–245.6) 60–170 6 (37.5)
Homocysteine (mmol/l) 8.5 (4.8–31.0) ,15 1 (6.3)
D-dimers (ng/ml) 141.5 (36.0–854.0) ,500 2 (12.5)
Free protein S (%) 89.4 (52.4–115.2) F: .55; M: .65 1 (6.3)
Protein C (%) 102.4 (54.0–150.0) .70 1 (6.3)
Antithrombin (%) 108.0 (89.0–133.0) .80 0 (0)
Anti-b2-GPI, IgM (MPL/ml) 3,5 (0.5–12.2) ,18 0 (0)
Anti-b2-GPI, IgG (GPL/ml) 2.1 (0.7–17.6) ,18 0 (0)
ACA, IgM (MPL/ml) 1.0 (0.0–13.3) ,15 0 (0)
ACA, IgG (GPL/ml) 2.0 (0.0–39.0) ,15 0 (0)
Lupus anticoagulant (ratio) 1.0 (0.8–1.2) ,1.2 0 (0)
Abbreviations: VTE, venous thromboembolism; ACA, anti-cardiolipin antibodies; anti-b2-GPI, anti-beta2 glycoprotein I antibodies; F, females; M, males.
Results are presented as median (minimum – maximum) values and as absolute (n) or relative (%) frequencies.
doi:10.1371/journal.pone.0081574.t004
Table 5. Absolute numbers of CEC and CEP in patients with
VTE, patients with MPN, and controls.
Group CEC/ml P* CEP/ml P*
Control 504 (186–1371) NA 295 (0–2110) NA
VTE 1231 (446–4272) ,0.001 168 (0–1698) 0.029
MPN 1305 (499–4616) ,0.001 311 (0–3791) NS
MPN (ET) 1305 (499–4239) 0.001 311 (83–2283) NS
MPN (PV) 1231 (594–4616) 0.001 385 (0–3791) NS
Abbreviations: CEC, circulating endothelial cells; CEP, circulating endothelial
progenitor cells; MPN, myeloproliferative neoplasms; VTE, venous
thromboembolism; ET, essential thrombocythaemia, PV, polycythaemia vera;
NA, not applicable; NS, not statistically significant.
Results are presented as median (minimum – maximum) values.
*Patients versus controls; Mann-Whitney test; p,0.05 was considered
statistically significant.
doi:10.1371/journal.pone.0081574.t005
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pathological clone as the hematopoietic cells, since these cells have
a same common precursor, the hemangioblast [51].
Moreover, in MPN patients we found a negative correlation
between the platelet and the CD54+ CEC counts. Maybe the fact
that most patients with MPN were on therapy had influenced the
number of platelets since it is already well established the ability of
hydroxyurea to reduce the platelet count [52], and to increase the
membrane-bound ICAM-1 [53].
Regarding to VTE patients, we found a positive correlation
between the number of CD54+ CEC and the AT plasma level. It
has been known that AT has anti-inflammatory activity, besides its
role in inhibiting thrombin and other coagulation enzymes. In
fact, several authors, studying different models, made the
observation that AT reduces the leukocyte adhesion and
inflammation [54,55,56]. Moreover, it was also shown that AT
suppresses platelet adhesion onto immobilized fibrinogen under
low flow condition [57]. The mechanism by which AT exerts these
effects in leukocyte and platelet adhesion and in ICAM-1 is still
unknown, but it was reported that AT administration increases the
levels of prostacyclin (PGI2), which may explain at least in part its
anti-inflammatory properties [58]. Considering these results, at
first sight it could be expected a negative correlation between the
numbers of CD54+ CEC and the levels of AT, curiously that was
not what we observed. Nevertheless, it should be noted that none
of these studies were done in VTE patients, but rather in induced
inflammatory models.
In VTE patients, there was a positive correlation between the
number of CD142+ CEC and the number of TE. This finding is
not surprising, as TF is a key indicator of the coagulation
activation [59], and previous studies in animal models have shown
that this molecule has an important role in thrombosis develop-
ment [60,61]
In conclusion, our results demonstrated that CEC numbers are
increased in patients with VTE and MPN, revealing endothelial
injury. In addition, the lower numbers of CEP detected in VTE, in
comparison to controls and MPN patients, would suggest a
deficiency on vascular repair. Our data also indicate that the
activation (CD54 and CD62E) and procoagulant (CD142) related
molecules are differentially expressed on CEC from patients with
VTE and MPN. It is also worth of note that total and activated-
CEC numbers and blood counts correlate differently in each
patient group. In addition, in patients with VTE we found a
positive correlation between the number of CD54+ CEC and the
AT levels, whereas the number of CD142+ CEC correlated
positively with the number of thrombosis. Altogether, the results
presented here reinforce the use of CEC and CEP as vascular
biomarkers and seem to indicate that those cells may have a role in
the mechanism involved in thrombosis, which appears to be
different in VTE and MPN patients.
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